Interestingly, previous association studies did not identify the PPARA gene as genome-wide significant, even though PPARA significantly contributes to the h2RV of ApoB and that both PPARA and APOB are involved in several lipid-related pathways (Supplementary Data 5), fatty liver disease, and dyslipidemias (Fig. 6), and identified as “druggable genome” in the DGIdb database (Supplementary Data 3). This evidence concerns the gene PPARA and fatty liver disease.